"The move is part of a major companywide program, announced nine weeks ago, to cut jobs and other costs and redesign the business of Madison, N.J.-based Wyeth, which is struggling with increased competition and fewer new drugs, like most pharmaceutical companies." D.D.,looks like a good counter argument to the Investment Managers' article in the FTimes. So I'll concede your implied guess was better than mine. -ggg-